Allergan Doubles Down on Aesthetics

Allergan Doubles Down on Aesthetics

September 14 was a big day for Allergan plc’s (NYSE: AGN) medical aesthetics business. The company announced its acquisition of Bonti, Inc., a privately held clinical-stage biotech that develops novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Later that same day, Allergan hosted a Medical Aesthetics Day in New York, at which its chief commerical officer, Bill Meury, said the company expects the unit to generate between $7 billion and $8 billion in sales by 2025. The business unit generated $3.8 billion in 2017. Allergan’s Medical Aesthetics unit includes the famous neurotoxin Botox (onabotulinumtoxinA), which was first approved in 1989 and... Read More »